Pilot Study of Minocycline (NPL-2003) in Adults With Obsessive-Compulsive Disorder (OCD)

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

9 participants

Study Classification

INTERVENTIONAL

Study Start Date

2008-08-31

Study Completion Date

2011-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Obsessive-compulsive disorder (OCD) is a common psychiatric illness that affects up to 2-3% of the population. People with OCD experience anxiety-provoking, intrusive thoughts, known as obsessions, and feel compelled to perform repetitive behaviors, or compulsions. The only medications proven effective for OCD are serotonin reuptake inhibitors (SRIs), but even with SRI treatment, most patients continue to experience significant OCD symptoms, impaired functioning, and diminished quality of life. Recent evidence suggest that a different neurotransmitter, glutamate, may contribute to the symptoms in OCD. Medications that target glutamate hold promise for ameliorating symptoms for those patients continuing to suffer from OCD. In this study we are recruiting patients to receive the drug NPL-2003, which is thought to modulate the neurotransmitter glutamate, added to whatever other OCD medications they are taking in a 12-week open label study.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study of NPL-2003 in Adolescents With Obsessive Compulsive Disorder (OCD)

NCT00515255

Obsessive Compulsive Disorder

TERMINATED PHASE2

Novel Medication Strategies Targeting Brain Mechanisms in Pediatric OCD

NCT01695291

Obsessive Compulsive Disorder

COMPLETED PHASE2

Memantine Augmentation in Treatment-Resistant Adults With Obsessive-Compulsive Disorder

NCT00956085

Obsessive-Compulsive Disorder

COMPLETED PHASE2

Mindfulness-Based Cognitive Therapy in a Clinical Sample of OCD Patients

NCT02217995

Obsessive-Compulsive Disorder

COMPLETED NA

Treatment of Obsessive-Compulsive Disorder (OCD) in Children

NCT00000384

Obsessive-Compulsive Disorder

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Obsessive Compulsive Disorder

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

Minocycline (NPL-2003)

Group Type EXPERIMENTAL

NPL-2003

Intervention Type DRUG

Minocycline (NPL-2003) daily for 12 weeks

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

NPL-2003

Minocycline (NPL-2003) daily for 12 weeks

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

5707 (Insitution Code name)

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Primary DSM-IV Diagnosis of OCD
* Currently on a stable and adequate dose of SRI (or history of prior SRI or CBT treatment meeting criteria for adequate trial)
* Patients not currently receiving an SRI or CBT will be included if they have undergone a prior SRI or CBT trial and they report no interest in pursuing another DRI or CBT trial at this time. Patients who have been on SRIs in the past must be free of SRIs for at least 6 weeks prior to participation
* Y-BOCS score of greater or equal to 16
* Physically health and females must be using effective contraception
* Sufficient severity of symptoms to warrant additional augmentation treatment
* Able to provide consent

Exclusion Criteria

* Ongoing treatment with other antibiotics and/or Accutane. Patients with lupus erythematosus
* Patients planning to start CBT during the study period or those who have begun CBT within the past 8 weeks
* Presence of psychotic symptoms or lifetime history of schizophrenia, bipolar disorder or other psychotic disorder
* Current major depressive disorder (patients must be free of the disorder for 3 months prior to enrollment). HAM-D must be \<18.
* Judged clinically to be at risk of suicide (suicidal ideation, severe depression or other factors
* Current eating disorder
* Severe renal insufficiency
* Documented history of hypersensitivity or intolerance to tetracycline antibiotics
* Concomitant use of anti-coagulant drugs, antacids, iron, calcium, magnesium, aluminum, zinc sales. Note:Concomitant psychotropic medications such as antipsychotics and benzodiazepines will be permitted as long as they have been stable for at least 4 weeks and remain stable during the course of the study.
* Current ETOH/drug abuse or dependence disorder of dependency in the past 3 months
* Female patients who are either pregnant or nursing

Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No